Suspended animation fmt
Reading File
"Suspended animation FMT" is a bit ambiguous. Let me clarify before diving in.
Asking for Preferences
What does 'FMT' mean in your question? · What aspect are you interested in?
I'll interpret this as fecal microbiota transplantation (FMT) in the context of suspended animation / emergency preservation and resuscitation (EPR) — a niche but emerging research area. Let me search both the medical library and recent literature simultaneously.
Finding Sources
Finding Sources
Searching PubMed
fecal microbiota transplantation AND suspended animation
Searching the Web
suspended animation FMT fecal microbiota transplant
No results link "suspended animation" directly to FMT. The web results are returning general FMT content — no research intersection with suspended animation / EPR. Let me search more specifically for the FMT + suspended animation angle, including the possibility this refers to cryopreservation of FMT samples or the gut microbiome during therapeutic hypothermia/EPR.
Searching PubMed
fecal microbiota transplantation AND cryopreservation storage
Searching PubMed
gut microbiome AND therapeutic hypothermia OR cardiac arrest resuscitation
Searching the Web
FMT "suspended animation" OR "emergency preservation" microbiota transplant research 2024 2025
There's no established research linking FMT specifically to suspended animation / EPR. The most likely interpretation of "suspended animation FMT" is frozen/cryopreserved FMT storage — i.e., keeping FMT samples in a state of "suspended animation" for long-term use. There's solid recent literature on this. Let me pull the key papers.
Reading Article
PMID: 39672770
Reading Article
PMID: 38544348
Reading Article
PMID: 40354906
Finding Sources
Now I have solid material. Let me also pull the Yamada's GI textbook section on FMT for foundational context.
Reading File
I now have enough to give a comprehensive answer. I'll interpret "suspended animation FMT" as the cryopreservation/long-term frozen storage of FMT products — the practice of putting microbial communities into a biologically inactive "suspended" state for banking and future use.
Fecal Microbiota Transplantation (FMT) in "Suspended Animation" — Frozen/Cryopreserved Storage
What It Means
"Suspended animation" in the FMT context refers to cryopreservation — freezing donor fecal material to halt microbial metabolism and preserve viability indefinitely, allowing stool banks to stockpile screened samples and deploy them on demand. This bypasses the logistical challenge of needing a fresh, same-day donor every time a patient requires treatment.
Why It Matters: The Logistics Problem
Fresh FMT requires a healthy, screened donor to produce a sample within hours of infusion. This creates real-world constraints:
- Donor availability and compliance
- Rapid processing time requirements
- No ability to pre-screen for rare pathogens (e.g., ESBL-producing organisms) that take days to culture
Frozen biobanked FMT solves all three problems — Yamada's Textbook of Gastroenterology notes that "systematic screening of donors and distribution of frozen screened samples have been initiated, and currently at least 10,000 FMTs are performed in the US annually." — Yamada's Textbook of Gastroenterology, 7th ed.
Freezing Protocols
Standard cryopreservation of FMT involves:
- Cryoprotectant addition (commonly 10% glycerol or DMSO) to prevent ice crystal formation
- Storage at −80 °C (deep freeze), which is the benchmark temperature
- Occasional −196 °C liquid nitrogen for ultra-long-term archiving
- Thawing at refrigerator temperature (4 °C) or room temperature prior to use
Lyophilization (freeze-drying) is an alternative "suspended animation" approach — water is removed under vacuum, producing a powder that can be encapsulated in oral capsules and stored at −20 °C or even 2–8 °C.
Evidence for Long-Term Viability
Frozen at −80 °C
12-month ex vivo study (Soukupova et al., 2024 [PMID 38544348]): 15 samples from 9 donors stored at −80 °C with cryoprotectant showed no significant decrease in bacterial viability (aerobic or anaerobic) over 12 months (p = 0.09). Variability between donors exceeded variability within-donor over time — meaning the donor itself matters more than storage duration.
24-month clinical study (Facchin et al., 2025 [PMID 39672770]): Donor stools frozen for 2 years contained viable bacteria comparable to fresh samples. Despite some taxonomic shifts (Blautia producta and Bifidobacterium adolescentis increased post-thaw), clinical success rates were 71.4% at 1 year and 100% at end of follow-up for CDI — comparable to fresh FMT benchmarks.
Lyophilized Capsules
Lyophilization stability study (Zain et al., 2025 [PMID 40354906]): Freeze-dried encapsulated FMT retained species diversity through manufacturing and after 36 weeks at −80 °C. Crucially, capsules were also stable at −20 °C and 2–8 °C for 24 weeks with no significant loss of viable bacteria — enabling refrigerator-temperature distribution without cold chain requirements.
Taxonomic Changes During Frozen Storage
Not all bacteria survive equally:
- Anaerobes are most vulnerable but show surprisingly minimal loss at −80 °C with cryoprotectant
- Some taxa increase post-thaw (artifact of competitive release or differential recovery): Blautia producta, Bifidobacterium adolescentis, C. aerofaciens, Erysipelotrichaceae
- Species richness dips when non-viable cells are excluded from analysis (seen with live/dead 16S sequencing)
The clinical implication: taxonomic composition changes slightly, but functional efficacy for CDI is preserved.
FDA-Approved Frozen Products
Two live biotherapeutic products (LBPs) derived from FMT research are now FDA-approved:
- Vowst (fecal microbiota spores, live-brpk) — oral capsules, 2023
- Rebyota (fecal microbiota, live-jslm) — rectal enema, 2022
A 2025 review in PMC notes that OpenBiome (the largest US stool bank supplying conventional frozen FMT) halted distribution of shipped frozen preparations on December 31, 2024, shifting the landscape toward these FDA-approved LBPs.
Key Safety Consideration for Frozen FMT
Frozen biobanking allows extensive pre-screening that fresh FMT cannot:
- Stool cultures for ESBL/CRE organisms (takes 2–5 days)
- PCR for viral pathogens (SARS-CoV-2, hepatitis E)
- Parasite and toxin testing
However, the fatal ESBL E. coli transmission cases (2019, FDA safety alert) involved screened frozen capsules — highlighting that no screening protocol eliminates all risk. Immunocompromised recipients require particular caution. — Yamada's Textbook of Gastroenterology, 7th ed.
Summary Table
| Parameter | Fresh FMT | Frozen (−80 °C) | Lyophilized Capsule |
|---|---|---|---|
| Shelf life | Hours | ≥24 months | 36 weeks (−80 °C); 24 weeks (2–8 °C) |
| Viability | Highest | Comparable at 12–24 months | Slightly reduced but clinically equivalent |
| Screening window | Limited | Full pathogen panel possible | Full pathogen panel possible |
| Cryoprotectant needed | No | Yes (glycerol/DMSO) | No (water removed) |
| Delivery route | Nasogastric/colonoscopic | Nasogastric/colonoscopic/enema | Oral capsule |
| CDI cure rate | ~85–90% | ~71–100% (studies vary) | Comparable |
If you meant something different by "suspended animation FMT" — such as FMT in the context of emergency preservation/resuscitation research, or another meaning entirely — let me know and I'll redirect.
This is a shared conversation. Sign in to Orris to start your own chat.